Ignite Creation Date:
2025-12-25 @ 4:11 AM
Ignite Modification Date:
2025-12-26 @ 3:09 AM
Study NCT ID:
NCT05286320
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-03-02
First Post:
2022-02-06
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.
Sponsor:
National Taiwan University Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-03-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-09-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-09-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-02-06
First Submit QC Date:
None
Study First Post Date:
2022-03-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-02-28
Last Update Post Date:
2023-03-02
Last Update Post Date Type:
ACTUAL